Why Apple Inc. (AAPL) Earnings Outperformance is Far From Guaranteed

Wells Fargo thinks Apple Inc. (AAPL) will outperform into earnings -- but options traders aren't so sure

by Alex Eppstein

Published on Jul 19, 2016 at 11:03 AM

Apple Inc. (NASDAQ:AAPL) has underwhelmed on the charts, provoking skepticism from the options crowd. Nonetheless, with AAPL earnings one week from tonight, Wells Fargo waxed optimistic on the stock, offering up some reasons why it should outperform into the event -- just like these two Dow stocks. For example, Wells Fargo said expectations on AAPL remain low, mentioning guidance for the December quarter, specifically. In spite of this, the brokerage firm still reduced its valuation range to $115-$125 from $120-$130.

That said, even the bottom of that range represents 15% upside to AAPL's current perch at $100. It's also worth keeping in mind that this key triple-digit level has acted as resistance repeatedly in 2016, and now corresponds to the falling 120-day moving average, which rejected the shares as recently as last month. In other words, AAPL may be tangling with double-barreled technical resistance.

As alluded to, options traders have been wagering on a pullback for the tech stock. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), AAPL's 50-day put/call volume ratio of 0.73 ranks just 4 percentage points from an annual peak. In other words, traders have been buying to open puts over calls at an accelerated clip in recent months.

On the flip side, negativity's been unwinding among short sellers. During the last two reporting periods, short interest plummeted 46%, and just 1% of the stock's float is sold short. However, if AAPL is again rejected by $100, a resumption in short selling could exacerbate pressure.

Also, Apple Inc. (NASDAQ:AAPL) remains at risk for potential downgrades and price-target cuts, especially if the company underwhelms in the earnings confessional. After all, 26 of 31 analysts rate the stock a "buy" or better, and its average 12-month price target of $122.78 resides in territory not explored since early November.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.